Brief: Ultragenyx Q4 EPS USD -1.39 Vs. IBES Estimate USD -1.29
13/02/2025 21:01
Feb 13 (Reuters) - Ultragenyx Q4 net income USD -133 million. * Q4 operating expenses USD 287 million
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx